Despite the aggressive nature of the disease, indicated by Ki-67 proliferation index of around 70% and double expression of BCL2 and c-MYC, the Pola-R-CHP regimen - a newer therapeutic combination - achieved rapid clinical and biochemical remission, including resolution of proteinuria and complete metabolic response on PET scan, reinforcing the therapeutic potential of this regimen in high-risk DLBCL with extranodal involvement. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.